Business
Crescita Obtains Shareholder Approval To Be Acquired By ClinActiv Holdings
LAVAL, Québec, May 14, 2026--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company") today announced that at its special meeting (the "Meeting") of shareholders (the "Shareholders") held in person earlier today, Shareholders voted overwhelmingly in favour of the special resolution (the "Arrangement Resolution") approving the previously announced plan of arrangement (the "Arrangement") involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary (th
About this update from Crescita Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4501,"height":1049,"url":"https://media.zenfs.com/en/business-wire.com/3dc28202a105cb2e0e072677913535d7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/f4BeB.9bZ3RW2v7nme77Zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIyNA--/https://media.zenfs.com/en/business-wire.com/3dc28202a105cb2e0e072677913535d7","width":960,"height":224},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/5u2kMuANuG9rM59yUoewdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE0OQ--/https://media.zenfs.com/en/business-wire.com/3dc28202a105cb2e0e072677913535d7","width":640,"height":149},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/CpTYcnPAWuVAaJoIOeNJ9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01NjA-/https://media.zenfs.com/en/business-wire.com/3dc28202a105cb2e0e072677913535d7","width":1200,"height":280}},"lazy":false},{"type":"text","content":"LAVAL, Québec, May 14, 2026--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company") today announced that at its special meeting (the "Meeting") of shareholders (the "Shareholders") held in person earlier today, Shareholders voted overwhelmingly in favour of the special resolution (the "Arrangement Resolution") approving the previously announced plan of arrangement (the "Arrangement") involving the Company, ClinActiv Holdings Inc. and its wholly-owned subsidiary (the "Purchaser"), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the "Shares") in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the "Arrangement Agreement"). The target purchase price is $0.80 per Share, subject to upward or downward adjustment based on the Company’s net working capital balance at the closing of the Arrangement, subject to a minimum purchase price of $0.75 per Share.","length":1131,"tagName":"p"},{"type":"text","content":"The Arrangement Resolution required approval of at least (i) two-thirds (66⅔ percent) of the votes cast by Shareholders, present in person or represented by proxy at the Meeting, and (ii) a simple majority (50 percent plus one) of t...